Welcome to our dedicated page for Alnylam Pharmaceuticals news (Ticker: ALNY), a resource for investors and traders seeking the latest updates and insights on Alnylam Pharmaceuticals stock.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) regularly issues news on its RNA interference (RNAi) therapeutics, commercial performance, pipeline progress, and corporate developments. As a company that has led the RNAi field from discovery to approved medicines, its announcements often highlight data from pivotal trials, regulatory milestones, and updates on marketed products such as AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
Investors following ALNY news can expect detailed coverage of clinical results across multiple therapeutic areas, including transthyretin‑mediated amyloidosis (ATTR), hypertension, bleeding disorders, neurological diseases, and metabolic conditions. Recent releases have described post hoc analyses from the HELIOS‑B Phase 3 study of AMVUTTRA in ATTR‑CM and hATTR‑PN, showing effects on gastrointestinal events, cardiac structure and function, and renal outcomes, as well as broader safety and efficacy profiles.
Alnylam’s news flow also includes financial and strategic updates. The company reports quarterly and annual net product revenues, trends in its TTR and rare disease franchises, and guidance associated with frameworks such as its Alnylam P5x25 and Alnylam 2030 strategies. Filings and press releases have discussed convertible senior notes, a revolving credit facility, and partial repurchases of outstanding debt, providing context on capital structure and liquidity.
Operational and manufacturing developments are another key news theme. Alnylam has announced expansion of its Norton, Massachusetts siRNA manufacturing facility and the integration of its siRELIS enzymatic ligation platform, which has been accepted into the FDA’s Emerging Technology Program. Corporate governance items, such as changes to the Board of Directors and executive responsibilities, are also disclosed. For anyone tracking ALNY, this news stream offers insight into clinical milestones, commercial execution, manufacturing scale‑up, and strategic direction in RNAi therapeutics.
Alnylam Pharmaceuticals (ALNY) has received marketing authorization from the European Commission for OXLUMO™ (lumasiran), an RNAi therapeutic aimed at treating primary hyperoxaluria type 1 (PH1), an ultra-rare disease. This approval fills a significant gap as there were previously no approved treatment options for PH1 in Europe. Clinical studies, ILLUMINATE-A and ILLUMINATE-B, showed lumasiran significantly reduced urinary oxalate levels. Alnylam intends to work with health authorities across Europe to ensure patient access while minimizing budget uncertainty for health services.
Alnylam Pharmaceuticals (Nasdaq: ALNY) reported positive interim data from its Phase 1 study of ALN-AGT, an RNAi therapeutic targeting angiotensinogen for hypertension treatment. Presented at the AHA Scientific Sessions 2020, data from 60 patients revealed significant AGT knockdown of up to 97.6% and considerable systolic and diastolic blood pressure reductions at 200 mg doses. The treatment demonstrated a favorable safety profile, with mild, transient adverse events observed. These results suggest a potential for innovative hypertension management with infrequent dosing, addressing the unmet need for improved patient adherence.
Alnylam Pharmaceuticals (Nasdaq: ALNY) announces virtual presentations at two upcoming conferences. The 29th Annual Credit Suisse Virtual Healthcare Conference is scheduled for November 9, 2020, at 12:30 pm ET, followed by the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 2:00 pm ET. Investors can access a live audio webcast of each presentation on Alnylam's website, with replays available within 48 hours post-event. Alnylam is a leader in RNA interference therapeutics, focused on innovative medicines for rare genetic and other severe diseases.
Summary not available.
Summary not available.
Alnylam Pharmaceuticals (Nasdaq: ALNY) will announce its third-quarter financial results for the period ending September 30, 2020, on November 5, 2020, before the U.S. markets open. The management team will host a conference call at 8:30 am ET on the same day to discuss the results and future expectations. Interested parties can access the call through a dedicated phone line or via a live audio webcast on the company's website. Alnylam focuses on RNA interference therapeutics aimed at treating various severe diseases with a robust product pipeline.
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced positive 6-month results from the ILLUMINATE-B Phase 3 study of lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1 (PH1). The study showed a 72% mean reduction in urinary oxalate levels among children under six. Lumasiran's safety profile was assessed as acceptable, with no severe adverse events reported. Lumasiran is also under FDA review, with a decision expected by December 3, 2020. If approved, it will be marketed as OXLUMO in the EU, following a Positive Opinion from the EMA's CHMP.
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced a positive opinion from the European Medicines Agency's CHMP for lumasiran, an RNAi therapeutic targeting the HAO1 mRNA for treating primary hyperoxaluria type 1 (PH1). PH1 is a rare disease affecting 3.5 to 4 individuals per million, characterized by excessive oxalate production leading to severe kidney damage. If approved by the European Commission, lumasiran will be marketed as OXLUMO™. Clinical trials indicate significant reductions in urinary and plasma oxalate levels, demonstrating a promising safety profile.
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced positive topline results from the ILLUMINATE-B Phase 3 study of lumasiran, an investigational RNAi therapeutic for primary hyperoxaluria type 1 (PH1). This trial is significant as it is the first assessing the safety and efficacy of lumasiran in children under six, including infants. The study enrolled 18 young patients and reported a clinically meaningful reduction in urinary oxalate levels. Lumasiran has received various FDA and EMA designations and a New Drug Application is pending with the FDA, set for review by December 3, 2020.
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced its participation in the Chardan Virtual 4th Annual Genetic Medicines Conference on October 5, 2020, at 4:15 PM ET. The company's management will provide a comprehensive overview during this event. A live audio webcast will be available on the Investors section of Alnylam's website, with a replay accessible within 48 hours post-presentation. Alnylam is at the forefront of RNA interference therapeutics, committed to innovating treatments for genetic and other serious diseases.
FAQ
What is the current stock price of Alnylam Pharmaceuticals (ALNY)?
What is the market cap of Alnylam Pharmaceuticals (ALNY)?
